Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:54:08 ON 17 APR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 06:56:01 ON 17 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 APR 2006 HIGHEST RN 880516-92-7
DICTIONARY FILE UPDATES: 14 APR 2006 HIGHEST RN 880516-92-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	1.07

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:56:06 ON 17 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 07:31:33 ON 17 APR 2006
FILE 'REGISTRY' ENTERED AT 07:31:33 ON 17 APR 2006

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	1.07

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10537346\10537346 clm 1 generic.str

chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 19 20
chain bonds :
1-2 2-3 3-4 3-20 4-5 4-18 5-6 6-19 7-8 7-13 8-9 10-11 10-14 11-12
exact/norm bonds :
1-2 4-5 4-18 5-6 6-19 7-8 7-13 8-9 10-11 10-14
exact bonds :
2-3 3-4 3-20 11-12

G1:[*1],[*2]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 18:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

```
=> search l1 sss sam
SAMPLE SEARCH INITIATED 07:32:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       79 TO ITERATE

100.0% PROCESSED       79 ITERATIONS                          45 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1047 TO     2113
PROJECTED ANSWERS:              498 TO     1302

L2            45 SEA SSS SAM L1

=> d scan

L2    45 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN    5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-(1-
      naphthalenyl)-, 2-(2-methylpropyl)-2-(methylsulfonyl)hydrazide,
      (2R,3S,5E)- (9CI)
MF    C26 H37 N3 O5 S

Absolute stereochemistry.
Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Imidazolidinebutanoic acid, β-[(hydroxyamino)carbonyl]-3,4,4-trimethyl-α-(2-methylpropyl)-2,5-dioxo-, 2-[(methylamino)carbonyl]-2-(phenylmethyl)hydrazide, (αR,βR)- (9CI)
MF C24 H36 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Piperidineacetic acid, 2-[(2R,3S,5E)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenyl-5-hexenyl]-1-(2-methylpropyl)hydrazide, mono(4-methylbenzenesulfonate) (salt) (9CI)
MF C28 H44 N4 O4 . C7 H8 O3 S

CM 1

Absolute stereochemistry.
Double bond geometry as shown.



CM 2



L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3-Furancarboxylic acid, 2-[(2R,3S,5E)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenyl-5-hexenyl]-1-(2-methylpropyl)hydrazide (9CI)
MF C26 H35 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[[3-(diethylamino)propyl]sulfonyl]-2-(2-methylpropyl)hydrazide, (2R,3S,5E)- (9CI)
MF C28 H48 N4 O5 S
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenebutanoic acid, α-[(formylhydroxyamino)methyl]-, 2-[(phenylamino)carbonyl]hydrazide (9CI)
MF C19 H22 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 6-Quinolinecarboxylic acid, 1,2,3,4-tetrahydro-1-(hydroxyacetyl)-, 2-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxoheptyl]hydrazide (9CI)
MF C21 H30 N4 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Benzofurancarboxylic acid, 2,3-dihydro-, 2-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxoheptyl]hydrazide (9CI)
MF C18 H25 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]hydrazide, (2R)- (9CI)
MF C18 H27 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[(2S)-2,4-diamino-1,4-dioxobutyl]-2-(2-methylpropyl)hydrazide, (2R,3S,5E)- (9CI)
MF C25 H39 N5 O5
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenehexanoic acid, β-[(hydroxyamino)carbonyl]-α-(2-methylpropyl)-, 2-[(dimethylamino)acetyl]-2-(phenylmethyl)hydrazide, (αR,βS)- (9CI)
MF C28 H40 N4 O4
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenebutanoic acid, β-[(hydroxyamino)carbonyl]-α-(2-methylpropyl)-, 2-(2-methylpropyl)-2-(methylsulfonyl)hydrazide, (αR,βS)- (9CI)
MF C20 H33 N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pentanoic acid, 2-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-, 2-[(methylamino)carbonyl]-2-(phenylmethyl)hydrazide, (2R)- (9CI)
MF C18 H28 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[(2S)-2-amino-1-oxopropyl]-2-(2-methylpropyl)hydrazide, monohydrochloride, (2R,3S,5E)- (9CI)
MF C24 H38 N4 O4 . Cl H

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-1,2,3-Triazole-1-acetic acid, 2-[(2R,3S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-1-(phenylmethyl)hydrazide, mono(4-methylbenzenesulfonate) (salt) (9CI)
MF C28 H36 N6 O4 . C7 H8 O3 S

CM 1

Absolute stereochemistry.



CM 2



L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-1,2,3-Triazole-1-acetic acid, 2-[(2R,3S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-1-[(2S)-2-methylbutyl]hydrazide (9CI)
MF C26 H40 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-butyl-2-[[(4,5-dihydro-3,5-dimethyl-4-isoxazolyl)amino]carbonyl]hydrazide (9CI)
MF C19 H35 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-Benzimidazole-2-carboxylic acid, 2-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxoheptyl]hydrazide (9CI)
MF C17 H23 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzeneacetic acid, 2-[3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hydrazide (9CI)
MF C18 H25 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[(2-methoxyphenyl)methyl]hydrazide, (2R)- (9CI)
MF C17 H27 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[(2S)-2-(methylamino)-1-oxopropyl]-2-(2-methylpropyl)hydrazide, (2R,3S,5E)- (9CI)
MF C25 H40 N4 O4
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):file caplus
'FILE CAPLUS' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.32	1.95

FILE 'CAPLUS' ENTERED AT 07:33:04 ON 17 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Apr 2006 VOL 144 ISS 17
FILE LAST UPDATED: 16 Apr 2006 (20060416/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l2
L3 7 L2

=> d l3 5-7 ti fbib abs

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of the release of tumor necrosis factor
AN 2000:15165 CAPLUS

DN 132:78850
TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of the release of tumor necrosis factor
IN Broadhurst, Michael John; Johnson, William Henry; Walter, Daryl Simon
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2000000465	A1	20000106	WO 1999-EP4223		19990617
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
	US 6239151	B1	20010529	US 1999-332809		19990614
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
	CA 2335245	AA	20000106	CA 1999-2335245		19990617
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
				WO 1999-EP4223	W	19990617
	AU 9947737	A1	20000117	AU 1999-47737		19990617
	AU 753660	B2	20021024			
				GB 1998-13919	A	19980627
				GB 1998-26491	A	19981202
				WO 1999-EP4223	W	19990617
	BR 9911588	A	20010320	BR 1999-11588		19990617
				GB 1998-13919	A	19980627
				GB 1998-26491	A	19981202
				WO 1999-EP4223	W	19990617
	EP 1089964	A1	20010411	EP 1999-931098		19990617
	EP 1089964	B1	20031029			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
				WO 1999-EP4223	W	19990617
	TR 200003731	T2	20010621	TR 2000-200003731		19990617
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
	JP 2002519339	T2	20020702	JP 2000-557226		19990617
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
				WO 1999-EP4223	W	19990617
	AT 253043	E	20031115	AT 1999-931098		19990617
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
				WO 1999-EP4223	W	19990617
	PT 1089964	T	20040331	PT 1999-931098		19990617
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202
	ES 2209460	T3	20040616	ES 1999-931098		19990617
				GB 1998-13919	A	19980626
				GB 1998-26491	A	19981202

ZA 2000007320 A 20010621 ZA 2000-7320 20001208
GB 1998-13919 A 19980626

OS MARPAT 132:78850
GI



I

AB Tile hydrazides I [R1 = alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl; R2 is an acyl group derived from an α-, β-, <γ- or δ-(amino, hydroxy or thiol) carboxylic acid in which the amino, hydroxy or thiol group is optionally lower alkylated or the amino group is optionally acylated, sulfonylated or amidated and in which any functional group present in a side-chain is optionally protected, or a group of the formula Het(CH2)mCO (Het is heterocyclyl, m = 0-4); R3 = H, alkyl, haloalkyl, cyanoalkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, heterocyclylcarbonylalkyl, alkenyl, alkynyl, cycloalkyl, arylalkenyl, aryl or heterocyclyl; R4 = alkyl, alkenyl, cycloalkyl, cycloalkyl alkyl or a grouping of the formula X-aryl, X-heteroaryl or (CH2)n-CH=CR5R6, where R5 and R6 together are alkylene in which one CH2 group is optionally replaced by a hetero atom, X is a spacer group, and n is 1 or 2] and their pharmaceutically acceptable salts were prepared as inhibitor of the release of tumor necrosis factor-α (TNF-α) from cells. Thus, (E)-2'-(D-alanyl)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-4-methylvalerohydrazide was prepared via reaction of N-(9-fluorenylmethoxycarbonyl)-D-alanine acid chloride with hydrazide derivative and shown to have IC50 = 303 nMol for inhibition of TNF-α.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of novel azapeptide type hydroxamic acid derivatives having a TNFα production inhibitory effect
AN 1999:511132 CAPLUS
DN 131:157991
TI Preparation of novel azapeptide type hydroxamic acid derivatives having a TNFα production inhibitory effect
IN Sugiyama, Naoki; Yoshida, Tomohiro; Takeda, Shinji; Maeda, Kazuhiro; Gotou, Tomokazu; Takemoto, Tadahiro
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9940063	A1	19990812	WO 1999-JP439	19990203

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			JP 1998-25664	A	19980206
AU 9922983	A1	19990823	AU 1999-22983		19990203
			JP 1998-25664	A	19980206
			WO 1999-JP439	W	19990203

OS MARPAT 131:157991

GI



I



AB Disclosed are azapeptide type hydroxamic acid derivs. represented by general formula [I; wherein X represents hydrogen or a hydroxyl-protective group; R1 represents hydrogen, hydroxy, amino, mercapto, alkoxy, alkyl, alkenyl, aryl or -(CH2)k-A; wherein A represents (un)substituted 5- or 6-membered N-heterocyclyl; k = 1-4; R2 represents hydrogen, (un)substituted alkyl or aryl; R3 represents hydrogen, (un)substituted alkyl, aryl, or heteroaryl or -(CONH)m-(CHR11)n-Y; wherein R11 represents hydrogen or (un)substituted alkyl; m is 0 or 1; n is 0-4; Y represents CO2R12, CONR12R12', or COR12 [wherein R12 and R12' represent hydrogen, (un)substituted alkyl or aryl or NR12R12 forms (un)substituted heterocyclyl]; and R4 represents alkyl, aryl, heteroaryl, -SO2R12, -CO-(CH2)q -NR12R12', -CONH-Z-R13 or -(CONH)m-(CHR11)n-Y, or R3 and R4 may together form a nitrogen-containing heterocycle; wherein R11, Y, m, R12, and R12' are same above; Z represents C2-4 alkylene; R13 represents hydroxy, amino, or NR12R12'] or pharmacol. acceptable salts thereof and medicinal compns. containing the same. Because of having a TNFα (tumor necrosis factor-α) production inhibitory effect, these compds. are useful in preventing and treating autoimmune diseases, inflammatory diseases, etc., for example, sepsis, MOF (multiple organ failure), chronic rheumatoid arthritis, Crohn's disease, cachexia, severe adynamia, systemic lupus erythematosus, asthma, type I diabetes and psoriasis. Thus, N-[4-hydroxy-(2R)-isobutylsuccinyl]aza-(2-naphthyl)alanyl-L-alanine benzyl ester was condensed with hydroxylamine hydrochloride using BPO reagent and 4-methylmorpholine in pyridine to give 58% N-[4-(N'-hydroxyamino)-(2R)-isobutylsuccinyl]aza-(2-naphthyl)alanyl-L-alanine benzyl ester which underwent amidation with MeNH2 in MeOH at room temperature for 30 min to give 33% N-[4-(N'-hydroxyamino)-(2R)-isobutylsuccinyl]aza-(2-naphthyl)alanyl-L-alanine N''-methylamide. In an ELISA assay, the title compound (II) in vitro showed IC50 of 0.53 μM for inhibiting the production of TNFα in THP-1 cells.

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor

release.
AN 1999:42740 CAPLUS
DN 130:110060
TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release.
IN Broadhurst, Michael John; Johnson, William Henry; Walter, Daryl Simon
PA F. Hoffmann-La Roche A.-G., Switz.
SO Ger. Offen., 64 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DE 19829229	A1	19990107	DE 1998-19829229		19980630
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
	US 6235787	B1	20010522	US 1998-98235		19980616
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
	CA 2295062	AA	19990114	CA 1998-2295062		19980618
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
				WO 1998-EP3683	W	19980618
	WO 9901428	A1	19990114	WO 1998-EP3683		19980618
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
	AU 9886273	A1	19990125	AU 1998-86273		19980618
	AU 725039	B2	20001005			
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
				WO 1998-EP3683	W	19980618
	EP 993442	A1	20000419	EP 1998-937498		19980618
	EP 993442	B1	20030423			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
				WO 1998-EP3683	W	19980618
	TR 9903281	T2	20000921	TR 1999-9903281		19980618
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
	BR 9810952	A	20000926	BR 1998-10952		19980618
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
				WO 1998-EP3683	W	19980618
	JP 2000513750	T2	20001017	JP 1999-506230		19980618
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
				WO 1998-EP3683	W	19980618
	AT 238277	E	20030515	AT 1998-937498		19980618
				GB 1997-13833	A	19970630
				GB 1998-3335	A	19980217
				WO 1998-EP3683	W	19980618

PT 993442	T	20030930	PT 1998-937498		19980618
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
ES 2195365	T3	20031201	ES 1998-937498		19980618
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
ZA 9805469	A	19981230	ZA 1998-5469		19980623
			GB 1997-13833	A	19970630
IT 1301792	B1	20000707	IT 1998-MI1441		19980624
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
FR 2765219	A1	19981231	FR 1998-8124		19980626
FR 2765219	B1	19991029			
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
GB 2326881	A1	19990106	GB 1998-14027		19980629
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
ES 2140348	A1	20000216	ES 1998-1359		19980629
ES 2140348	B1	20001016			
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
MX 9911668	A	20000531	MX 1999-11668		19991214
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
			WO 1998-EP3683	W	19980618
BG 104050	A	20001229	BG 1999-104050		19991228
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
			WO 1998-EP3683	W	19980618
NO 9906534	A	20000223	NO 1999-6534		19991229
			GB 1997-13833	A	19970630
			GB 1998-3335	A	19980217
			WO 1998-EP3683	W	19980618

OS MARPAT 130:110060
GI



I

AB Title compds. [I; Y = CO, SO2; R1 = alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl; R2 = alkyl, haloalkyl, aralkyl, aralkenyl, aryl, alkoxy, alkoxycarbonyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl, aralkenyl, aryl, heterocyclyl; R2R3 = 5-7 membered cyclic amide, imide, sulfonamide, or urethane; R4 = alkyl, alkenyl, cycloalkylalkyl, ArX, HetX, etc.; Ar = aryl; Het = heteroaryl; X = spacer], were prepared Thus, (E)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-(methanesulfonyl)-4-methyl-2'-phenylvalerohydrazide (multistep preparation given) inhibited TNFα and TGFα release with IC50 = 437 nM and 210 nM, resp.

=> save temp l3 cmpdanswrs/a
ANSWER SET L3 HAS BEEN SAVED AS 'CMPDANSWRS/A'

=> logoff hold
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	10.52	12.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 07:35:54 ON 17 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:37:57 ON 31 OCT 2006

=>
=> logoff hold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:38:14 ON 31 OCT 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 06:41:44 ON 31 OCT 2006
FILE 'HOME' ENTERED AT 06:41:44 ON 31 OCT 2006

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

=> logoff hold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:42:05 ON 31 OCT 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 06:58:22 ON 31 OCT 2006
FILE 'HOME' ENTERED AT 06:58:22 ON 31 OCT 2006

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?

Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	1.26

FILE 'REGISTRY' ENTERED AT 07:00:41 ON 31 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 OCT 2006 HIGHEST RN 911633-89-1
DICTIONARY FILE UPDATES: 30 OCT 2006 HIGHEST RN 911633-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10537346\10537346 clm 1 correct genus.str





chain nodes :
1 2 3 4 7 8 9 10 11 12 13 14 18 19 20
ring nodes :
5 6 21
chain bonds :
1-2 2-3 3-4 3-20 4-5 4-18 6-19 7-8 7-13 8-9 10-11 10-14 11-12
ring bonds :
5-6 5-21 6-21
exact/norm bonds :
1-2 4-5 4-18 5-6 5-21 6-19 6-21 7-8 7-13 8-9 10-11 10-14
exact bonds :
2-3 3-4 3-20 11-12

G1:[*1],[*2]

G2:C,O,S,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 18:CLASS 19:CLASS 20:CLASS
21:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2]
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam
SAMPLE SEARCH INITIATED 07:01:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1 sss full
FULL SEARCH INITIATED 07:01:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 144 TO ITERATE

100.0% PROCESSED 144 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.01

L3 45 SEA SSS FUL L1

=> d scan

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-phenyl- (9CI)
MF C21 H30 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):45

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]- (9CI)
MF C27 H40 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-pyridinylcarbonyl)- (9CI)
MF C19 H26 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(2-methoxyphenyl)- (9CI)
MF C21 H30 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(2-furanylcarbonyl)hexahydro- (9CI)
MF C19 H27 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(3-furanylcarbonyl)hexahydro- (9CI)
MF C19 H27 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(2,4-difluorophenyl)tetrahydro- (9CI)
MF C21 H28 F2 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(2-furanylcarbonyl)- (9CI)
MF C18 H25 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-methoxybenzoyl)- (9CI)
MF C21 H29 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(3-methoxyphenyl)- (9CI)
MF C21 H30 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-[4-(trifluoromethyl)benzoyl]- (9CI)
MF C22 H28 F3 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]- (9CI)
MF C24 H35 N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-(2-methoxyphenyl)- (9CI)
MF C22 H32 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-[4-(trifluoromethyl)benzoyl]- (9CI)
MF C21 H26 F3 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(3-pyridinylcarbonyl)- (9CI)
MF C19 H26 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinebutanamide, β-(cyclopentylmethyl)-2-(2-furanylcarbonyl)tetrahydro-N-hydroxy-γ-oxo-, (βR)- (9CI)
MF C19 H27 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(4-methoxybenzoyl)- (9CI)
MF C22 H31 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-(3-methoxyphenyl)-(9CI)
MF C22 H32 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxylic acid, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI)
MF C18 H31 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-(cyclohexylcarbonyl)-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]- (9CI)
MF C20 H33 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-phenyl- (9CI)
MF C20 H28 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(methoxyacetyl)- (9CI)
MF C17 H29 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-fluorobenzoyl)hexahydro- (9CI)
MF C21 H28 F N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-[4-(trifluoromethyl)phenyl]- (9CI)
MF C22 H29 F3 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(methoxyacetyl)- (9CI)
MF C16 H27 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-(1,3-benzodioxol-5-ylcarbonyl)-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]- (9CI)
MF C21 H27 N3 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-[4-(trifluoromethyl)phenyl]- (9CI)
MF C21 H27 F3 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(4-pyridinylcarbonyl)- (9CI)
MF C20 H28 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro- (9CI)
MF C23 H28 F6 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-methyl-N-phenyl- (9CI)
MF C22 H32 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(phenylacetyl)- (9CI)
MF C21 H29 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(3-furanylcarbonyl)- (9CI)
MF C18 H25 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinebutanamide, β-(cyclopentylmethyl)tetrahydro-N-hydroxy-γ-oxo-2-[(phenylamino)carbonyl]-, (βR)- (9CI)
MF C21 H30 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-(1,3-benzodioxol-5-ylcarbonyl)-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro- (9CI)
MF C22 H29 N3 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(4-fluorophenyl)tetrahydro- (9CI)
MF C21 H29 F N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxylic acid, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-, 1,1-dimethylethyl ester (9CI)
MF C19 H33 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]- (9CI)
MF C23 H33 N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(4-fluorophenyl)- (9CI)
MF C20 H27 F N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-benzoyl-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro- (9CI)
MF C21 H29 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(phenylacetyl)- (9CI)
MF C22 H31 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)tetrahydro- (9CI)
MF C23 H32 N4 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-benzoyl-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]- (9CI)
MF C20 H27 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-fluorobenzoyl)- (9CI)
MF C20 H26 F N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-methyl-N-phenyl- (9CI)
MF C21 H30 N4 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyridazine, 1-(cyclohexylcarbonyl)-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro- (9CI)
MF C21 H35 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	168.64

FILE 'CAPLUS' ENTERED AT 07:02:08 ON 31 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 Oct 2006 VOL 145 ISS 19
FILE LAST UPDATED: 30 Oct 2006 (20061030/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l3
L4 1 L3

=> d l4 ti fbib abs it

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acylpyridazines and acylpyrazolidines as antibacterial agents.
AN 2004:493687 CAPLUS
DN 141:54351

TI Preparation of acylpyridazines and acylpyrazolidines as antibacterial agents.

IN East, Stephen Peter
PA Vernalis (Oxford) Ltd., UK

SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050638	A1	20040617	WO 2003-GB5179	20031201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				GB 2002-28365	A 20021205
	AU 2003285545	A1	20040623	AU 2003-285545	20031201
				GB 2002-28365	A 20021205
				WO 2003-GB5179	W 20031201
	EP 1567504	A1	20050831	EP 2003-778542	20031201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				GB 2002-28365	A 20021205
				WO 2003-GB5179	W 20031201
	US 2006128811	A1	20060615	US 2006-537346	20060123
				GB 2002-28365	A 20021205
				WO 2003-GB5179	W 20031201

OS MARPAT 141:54351

AB QCHR1CHR2CONR3NR4YA [Q = N(OH)CHO, CONH(OH); Y = CO, CS, SO, SO2; R1 = H, alkyl, haloalkyl, OH, alkoxy, alkenyloxy, halo, amino, alkylamino, dialkylamino; R2 = (substituted) alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkylalkyl, aralkyl, heterocyclylalkyl, aminoalkyl; R3R4 = atoms to form a (substituted) saturated 4-7 membered heterocyclic ring which may be fused to a second carbocyclic or heterocyclic ring; A = amino, R5, OR5; R5 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, alkoxyalkyl, alkylthioalkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, etc.], were prepared Thus, 3-N-benzyloxyformylamino-(2R)-cyclopentylmethylpropionic acid in DMF at 0° was treated with EDAC and HOBt followed by stirring for 15 min. and addition of 1,2-diazacyclohexane hydrochloride and diisopropylethylamine; the mixture was kept at 0° for 1 h and warmed to room temperature and left for 5 h to give 65% N-benzyloxy-N-[(2R)-cyclopentylmethyl-3-oxo-3-(tetrahydropyridazin-1-yl)propyl]formamide. The latter in CH2Cl2 at 0° was treated with 2-furoyl chloride and diisopropylethylamine followed by stirring for 30 min. and warming to room temp and kept for 16 h to give 89% diacyl derivative, which was hydrogenolyzed in MeOH over Pd/C to give 100% (2R)-cyclopentylmethyl-3-[2-(furan-2-carbonyl)tetrahydropyridazin-1-yl]-3-oxopropylformamide. This inhibited S. pneumoniae with a min. inhibitory concentration of 0.5-2 μg/mL.

IT Infection
(bacterial, treatment; preparation of acylpyridazines and acylpyrazolidines as antibacterial agents)

IT Antibacterial agents
Drug delivery systems
Human
(preparation of acylpyridazines and acylpyrazolidines as antibacterial

agents)
IT 706778-35-0P 706778-36-1P 706778-37-2P
706778-38-3P 706778-39-4P 706778-40-7P
706778-41-8P 706778-42-9P 706778-43-0P
706778-44-1P 706778-45-2P 706778-46-3P
706778-47-4P 706778-48-5P 706778-49-6P
706778-50-9P 706778-51-0P 706778-52-1P
706778-53-2P 706778-54-3P 706778-55-4P
706778-56-5P 706778-57-6P 706778-58-7P
706778-59-8P 706778-60-1P 706778-61-2P
706778-62-3P 706778-63-4P 706778-64-5P
706778-65-6P 706778-66-7P 706778-67-8P
706778-68-9P 706778-69-0P 706778-70-3P
706778-71-4P 706778-73-6P 706778-74-7P
706778-75-8P 706778-76-9P 706778-77-0P
706778-78-1P 706778-79-2P 706778-80-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylpyridazines and acylpyrazolidines as antibacterial agents)
IT 103-71-9, Phenyl isocyanate, reactions 527-69-5, 2-Furoyl chloride 700-87-8, 2-Methoxyphenyl isocyanate 4285-42-1, N-Methyl-N-phenylcarbamoyl chloride 16588-74-2, 3,5-Bistrifluoromethylphenyl isocyanate 57699-91-9 89990-53-4 301684-75-3 325796-41-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of acylpyridazines and acylpyrazolidines as antibacterial agents)
IT 706778-81-6P 706778-82-7P 706778-83-8P 706778-84-9P 706778-85-0P
706778-86-1P 706778-87-2P 706778-88-3P 706778-89-4P 706778-90-7P
706778-91-8P 706778-92-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylpyridazines and acylpyrazolidines as antibacterial agents)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.53	172.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 07:02:45 ON 31 OCT 2006